Acute parvovirus B19-associated inflammatory musculoskeletal disease: clinical phenotypes and remission trajectories from the GIRRCS network
Authors' conclusion
Acute parvovirus B19-associated inflammatory musculoskeletal disease may mimic inflammatory rheumatic disease in adults referred for rheumatological assessment. Most patients achieved remission without disease-modifying escalation, although remission timing varied and one patient required biologic therapy for persistent inflammatory disease.
Study context
- Population
- Adults with new-onset inflammatory musculoskeletal manifestations, positive anti-parvovirus B19 IgM and symptom onset within 4 weeks, GIRRCS rheumatology unitsfollow-up data for 21
- Participants
- 24 adults
- Outcome
- Time to first documented clinical remission (symptom onset to first rheumatologist-confirmed resolution of inflammatory musculoskeletal manifestations)
Methodological detailsnon-interventional
- Non-interventional
Main finding
As reported in the abstract
Clinical remission without DMARD escalation (of 21 with follow-up)
20
95.2%
Documented remission timing, median (IQR; range)
21 days
IQR 10–60; range 7–135
Observational data: associations, not effects.
Further findings
Clinical phenotype at presentation
- Polyarticular involvement
- 14 (58.3%)
- Oligoarticular involvement
- 10 (41.7%)
- Enthesitis
- 4 (16.7%)
- Inflammatory markers modestly elevated
- Most patients with complete autoantibody data seronegative
- Dactylitis absent
- Selective imaging documented inflammatory abnormalities in clinically indicated examinations
Biologic escalation for persistent inflammatory disease
- Patients requiring biologic escalation
- 1
Predictors of documented remission timing
- Exploratory regression analyses did not identify robust associations with documented remission timing
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →